At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 49 enrolled
Drug / intervention
Albuterol-HFA-MDI +1 moredrug
Likely dose
Albuterol-HFA-MDI 90 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Single-Dose Efficacy of Albuterol-HFA-BAI and Albuterol-HFA-MDI in Asthmatics With Poor Inhaler Coordinating Ability
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Sep 17, 2007·Updated Sep 7, 2022
In Brief
A Phase 4 clinical trial evaluating Albuterol-HFA-MDI and Albuterol-HFA-BAI for Asthma. Completed, enrolled 49 participants across 5 sites.
Detailed Summary
This is a research study designed to compare the single-dose efficacy of albuterol-hydrofluoroalkane-breath-actuated inhaler (HFA-BAI) and albuterol-HFA-metered-dose inhaler (MDI) in asthmatics with poor inhaler coordinating abilities.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
First PostedSep 2007
Primary CompletionOct 2008
TodayJul 2026
First PostedSep 17, 2007
Enrollment StartJul 25, 2007
Primary CompletionOct 24, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.8 years ago
Interventions
Albuterol-HFA-MDIdrug
Inhalation Aerosols, 90 mcg, 1 dose per treatment period
Albuterol-HFA-BAIdrug
Inhalation Aerosol (Breath-Actuated), 90 mcg, 1 dose per treatment period.